Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.935
-0.135-1.34%
Volume:27.53M
Turnover:270.86M
Market Cap:114.47B
PE:24.99
High:10.040
Open:9.955
Low:9.670
Close:10.070
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.50
T/O Rate:0.24%
Dividend:0.29
Dividend Rate:2.92%
EPS(LYR):0.398
ROE:20.90%
ROA:10.70%
PB:2.60
PE(LYR):24.99
PS:3.12

Loading ...

Clinical Data Readouts Take Center Stage as Chinese Biotech Firms Surge; CSPC Pharma Climbs Over 4% While Huabao's HK Biotech ETF Holds Key Support

Deep News
·
Sep 03

Movement Alert|CSPC PHARMA Rises 3.11% in Regular Trading, Multiple Pipeline Milestones Drive Momentum

Market Focus
·
Sep 03

CSPC Pharmaceutical Initiates Phase I Clinical Trial of Syh2056 Tablets in China

Reuters
·
Sep 01

CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China

MT Newswires Live
·
Sep 01

CSPC Pharma Initiates Depression Drug Candidate Trial in China

MT Newswires Live
·
Sep 01

CSPC Pharma Launches Phase I Trial of Novel 5-HT2A Partial Agonist SYH2056 for Depression in China

Bulletin Express
·
Sep 01

CSPC Pharma Secures Third NMPA Breakthrough Therapy Designation for EGFR-Targeting ADC SYS6010 in Recurrent/Metastatic Head-and-Neck Cancer

Bulletin Express
·
Sep 01

CSPC Pharmaceutical - Sys6010 Granted Breakthrough Therapy Designation by Nmpa in China for R/M Hnscc

THOMSON REUTERS
·
Sep 01

CSPC Pharma Begins Trial for Weight Management Drug in China

MT Newswires Live
·
Aug 31

CSPC Pharma Begins Phase I Trial of SYH2092, a Novel Amylin Receptor Agonist for Obesity Management

Bulletin Express
·
Aug 31

CSPC Pharma Advances Weight Management Pipeline With Phase 1 Trial Kickoff

Stock News
·
Aug 31

CSPC Pharma Wins China NMPA Clearance to Start Phase 1 Trial of Syh2092 Obesity Drug

Reuters
·
Aug 31

CSPC Pharmaceutical - Initiates Phase I Clinical Trial of Syh2092 Injection for Weight Management in China

THOMSON REUTERS
·
Aug 31

CSPC Pharmaceutical Group Stock Sheds 3.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 31

Movement Alert|CSPC PHARMA Declines 3.04% in Regular Trading, Trading at HK$9.215

Market Focus
·
Aug 31

CSPC Pharma Initiates Phase II Trial of SYH2069 Dual GLP-1/GIP Agonist for Obesity Management in China

Bulletin Express
·
Aug 28

CSPC Pharmaceutical Group Stock Sheds 1.5% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 28

CSPC Pharma Gets Trial Nod for Weight Management Drug in China

MT Newswires Live
·
Aug 27

CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China

Stock News
·
Aug 27

CSPC Pharma Secures NMPA Green Light for SYH2092, a Long-Acting Amylin Receptor Agonist Targeting Obesity and Type 2 Diabetes

Bulletin Express
·
Aug 27